Intranasal angiotensin II directly influences central nervous regulation of blood pressure
Intranasal angiotensin II directly influences central nervous regulation of blood pressure
复制标题
DOI：
10.1016/s0895-7061(98)00095-8
复制
发表时间：
1998-08-01
影响因子：
3.2
通讯作者：
Fehm, HL
中科院分区：
文献类型：
--
作者：
Derad, I;Willeke, K;Fehm, HL
一些多肽的鼻内给药已被证明直接影响中枢神经功能，从而指出这些物质在人类中的鼻-脑通路。本研究调查了鼻内给药血管紧张素II （ANG II）是否以不同于静脉给药ANG II的方式影响心血管控制的中枢神经功能。在平衡交叉设计中，12名健康男性接受ANG II静脉注射（2.5 μ g）、ANG II鼻内注射（400 μ g）和安慰剂治疗。每10分钟评估一次血管紧张素、血管加压素、去甲肾上腺素和肾上腺素的血浆水平；血压、心率和全身血管阻力均通过Dinamap和连续无创体体积脉搏波描记仪测量。此外，还测量了激活感和情绪。鼻内和静脉给药引起血浆中ANG II水平的相同升高，并引起血压的急性升高，其大小和持续时间相当。然而，随后的血压变化取决于静脉和鼻内给药ANG II；经静脉给药后血压仍维持在中等水平升高，但经鼻给药后血压恢复正常甚至降至正常水平以下。鼻内ANG II也抵消了静脉注射ANG II后观察到的去甲肾上腺素水平的下降。鼻内而非静脉注射ANG II增强了加压素的血浆浓度。这种效果的分化模式与动物脑室内给药ANG II的效果相似，表明鼻内给药后的效果反映了ANG II的直接中枢神经作用。Am J Hypertens 1998；[j]中华高血压病杂志，1998。
Intranasal administration of some peptides has been shown to directly influence central nervous functions, thus pointing to a nose-brain pathway for these substances in humans. The present study investigated whether intranasal administration of angiotensin II (ANG II) affects central nervous functions of cardiovascular control in a different way from intravenously administered ANG II. In a balanced cross-over design 12 healthy men were treated with ANG II intravenously (2.5 mu g) ANG II intranasally (400 mu g), and placebo. Angiotensin II, vasopressin, norepinephrine, and epinephrine plasma levels were assessed every 10 min; blood pressure, heart rate, and systemic vascular resistance were measured by a Dinamap, and by continuous, noninvasive body plethysmography. Also, feelings of activation and mood were measured. Intranasal and intravenous administration invoked equivalent increases in plasma levels of ANG II, and induced an acute rise in blood pressure of comparable size and duration. However, subsequent blood pressure profiles differed dependent on intravenous and intranasal ANG II administration; after intravenous ANG II administration blood pressure remained enhanced at an intermediate level, but it returned to normal or even decreased below normal levels after intranasal ANG II administration. Intranasal ANG II also counteracted the decrease in norepinephrine levels observed after intravenous administration of ANG II. Intranasal but not intravenous ANG II enhanced plasma concentrations of vasopressin. This diverging pattern of effects bears similarities with effects of intracerebroventricular administration of ANG II in animals, suggesting that the effects after intranasal administration reflect a direct central nervous action of ANG II. Am J Hypertens 1998;11:971-977 (C) 1998 American Journal of Hypertension, Ltd.